@jasonposton's KPV plus BPC-157 combo claims, fact-checked

What did @jasonposton actually say?

Jason Poston describes a compounded oral pill that combines BPC-157 and KPV, pitching it as an upgrade from injectable BPC-157. He calls KPV "the newest anti-inflammatory peptide" and lists a range of conditions it supposedly helps, including eczema, acne, ulcerative colitis, and general wound healing. His core pitch: "you get two bang for your buck" with one capsule.

He frames both compounds as established healing tools, implies oral BPC-157 works comparably to injectable, and positions the combination as a straightforward clinical win. None of those assumptions are as clean as he makes them sound.

Does the science back this up?

Partly, but the jump from lab research to clinical product is bigger than Poston acknowledges. The science on KPV and BPC-157 individually is real but thin in humans, and oral bioavailability of either compound is an open question that he skips entirely.

BPC-157 (Body Protection Compound 157) has a legitimate preclinical base. Animal studies, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design through the 2010s and 2020s, show anti-inflammatory and tissue-repair effects across gut, tendon, and muscle models. Those results are interesting. They are not, however, human clinical trials, and the FDA has flagged BPC-157 as lacking sufficient evidence for compounding under 503B standards.

KPV is a tripeptide fragment of alpha-MSH (alpha-melanocyte-stimulating hormone). Research by Dalmasso et al. (2008, Journal of Proteome Research) and Kannengiesser et al. (2008, Peptides) showed anti-inflammatory effects in colitis models and intestinal epithelial cells. Again, these are cell and animal studies. Calling KPV "the newest anti-inflammatory peptide" is loose language. It has been studied since at least the early 2000s.

What did they get wrong (or right)?

Poston gets credit for accurately describing BPC-157's general reputation as a wound-healing and anti-inflammatory compound. That framing is consistent with the preclinical literature. He also correctly identifies KPV's studied areas, including inflammatory bowel disease and skin conditions. Those are real research targets.

Where he goes wrong is significant. Saying BPC-157 is now available "in pill form" as though oral and injectable versions are equivalent is misleading. BPC-157 is a peptide. Peptides are broken down in the GI tract. The oral bioavailability question has not been resolved in peer-reviewed human pharmacokinetic data. Some compounders add protective coatings or use enteric capsules, but Poston makes no mention of this complexity.

He also implies these compounds treat conditions like ulcerative colitis and eczema in a clinical sense. That overstates the evidence. Stating KPV "has been used in the treatment of ulcerative colitis" without clarifying that this is based on animal and in vitro data, not approved human treatment protocols, is the kind of claim that misleads patients into expecting outcomes the research does not yet support.

What should you actually know?

If you are considering a compounded KPV and BPC-157 oral product, here is the honest picture. Both compounds have legitimate scientific interest. Neither is FDA-approved for any indication. Compounded peptides exist in a regulatory gray zone, and the quality, purity, and dosing consistency of compounded products vary significantly depending on the pharmacy.

Oral delivery of peptides is genuinely challenging. Without published pharmacokinetic data showing how much of either compound reaches systemic circulation after oral dosing in humans, any efficacy claim for the oral form is speculative. This does not mean the product is useless. It means the evidence threshold Poston implies has been cleared has not actually been cleared.

• BPC-157 was placed on the FDA's list of bulk drug substances that cannot be used in compounding without further review in 2023, which is a regulatory fact worth knowing before purchasing.
• KPV's anti-inflammatory mechanisms are biologically plausible and backed by cell and animal studies, but no completed human clinical trials exist as of early 2025.
• "Compounded" does not mean "equivalent to studied forms." Ask any prescriber what delivery method was used in the underlying research before assuming the pill form performs the same way.

Bottom line: is this worth your attention?

The underlying science on both peptides is worth following. The clinical claims in this video outrun the evidence. If a provider is prescribing this combination for you, ask them directly what human data informs the dosing and delivery method. If they cannot answer that, you have your answer about how seriously the evidence is being applied.